A global multi-center phase Ia study of GQ1001, a novel anti-HER2 antibody-drug conjugate, demonstrated excellent tolerability and promising anti-tumor activity in patients with HER2 positive advanced solid tumors. The study, conducted across several countries, aimed to assess the safety, pharmacokinetics, and preliminary efficacy of GQ1001, determining a recommended dose for expansion without reaching the maximum tolerated dose. The findings suggest GQ1001's potential as a treatment option for HER2 positive cancers, with a safety profile attributed to its innovative conjugation technology.
The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.